Incyte Lifts 2026 Sales Outlook To $5.21 Billion-$5.30 Billion Even As Vega Charge Drives $784.8 Million Quarterly Loss
A one-time $1.23 billion Vega charge swamped profit, while Opzelura and cancer-drug sales grew and guidance rose.
Incyte, the biopharmaceutical company behind the blood-cancer drug Jakafi and the skin cream Opzelura, raised its 2026 net sales guidance to $5,210 million to $5,300 million on Thursday, even as a one-time $1.23 billion charge for buying Vega Therapeutics pushed it to a third-quarter net loss of $784.8 million. The prior range was $5,130 million to $5,260 million.
Sales up 14%, profit gone
Total revenue in the quarter was $1.56 billion, up 14% from a year earlier, and total net sales were $1.32 billion, also up 14%. Jakafi, the biggest product, brought in $827 million, up 4%, which the company said was driven by a 12% rise in paid demand.
Opzelura cream reached $255 million, up 36%, on higher patient demand in atopic dermatitis and vitiligo plus better net pricing after a line-extension settlement in the second quarter. Hematology and oncology products hit $235 million, up 38%, led by Niktimvo, Zynyz and Monjuvi/Minjuvi.
The bottom line went the other way. Incyte posted a GAAP net loss of $784.8 million, or $3.86 per share, against a $424.2 million profit a year earlier. R&D spending rose to $1.79 billion because of the $1.23 billion Vega charge; without it, R&D grew 11% and GAAP operating income rose 18%.
Guidance raised across three lines
Opzelura guidance now stands at $1,100 million to $1,120 million, from $1,050 million to $1,100 million. Hematology and oncology moves to $890 million to $910 million, from $860 million to $890 million. Jakafi and expense guidance are unchanged.
Cash and marketable securities were $3.9 billion at September 30, against $3.6 billion at the end of 2025. CEO Bill Meury said the company has built a "durable core business beyond Jakafi."
Vega, Medicaid and the pipeline
Incyte completed the Vega purchase in July for $1.25 billion. It brought latarcibart, an antibody in late-stage testing for von Willebrand disease, a bleeding disorder. Star Therapeutics, Vega's parent, can earn up to $750 million more if sales milestones are met.
In August, Incyte agreed with the federal Medicaid agency to let state programs buy Jakafi at prices aligned with a group of other industrialized nations. The company expects that to exempt it from certain future federal pricing mandates, including the proposed GUARD and GLOBE models.
Phase 3 data for povorcitinib in prurigo nodularis and for ruxolitinib cream in hidradenitis suppurativa are due in the fourth quarter, along with a European Commission decision on povorcitinib.
Sources
- 8-K Filing — INCYTE CORP (INCY) — SEC EDGAR
- Exhibit incy-q32026xexx991.htm — INCYTE CORP 8-K exhibit — SEC EDGAR
- Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint? — Yahoo Finance
- Does Genmab Trial Deal Change The Bull Case For Incyte (INCY)? — Yahoo Finance
- ESMO: Incyte feels ‘neck and neck’ with RevMed in KRAS G12D race — fiercebiotech.com
- Incyte (INCY) Starts KRAS G12D Colorectal Cancer Trial Collaboration — Yahoo Finance
- Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer — businesswire.com